We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+10.98%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$40.7B
AUM Growth
-$4.56M
(-0.01%)
Cap. Flow
-$3.46B
Cap. Flow
% of AUM
-8.5%
Top 10 Holdings %
Top 10 Hldgs %
19.9%
Holding
801
New
88
Increased
169
Reduced
396
Closed
90
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RTX Corp
RTX
|
+$165M |
| 2 |
Costco
COST
|
+$134M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$126M |
| 4 |
Johnson Controls International
JCI
|
+$121M |
| 5 |
3M
MMM
|
+$112M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.48B |
| 2 |
Apple
AAPL
|
+$136M |
| 3 |
Marathon Petroleum
MPC
|
+$123M |
| 4 |
CenterPoint Energy
CNP
|
+$123M |
| 5 |
Under Armour
UAA
|
+$117M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.42% |
| 2 | Healthcare | 16.85% |
| 3 | Financials | 12.9% |
| 4 | Consumer Discretionary | 10.95% |
| 5 | Industrials | 10.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AKRO
501
DELISTED
Akero Therapeutics
AKRO
| $12M | 0.03% |
540,000
+15,000
| +3% | +$310K |
|
502
C.H. Robinson
CHRW
$17.4B
| $12M | 0.03% |
153,100
-7,500
| -5% | -$597K |
|
503
Packaging Corp of America
PKG
$21.9B
| $11.9M | 0.03% |
106,600
-5,200
| -5% | -$574K |
|
504
Live Nation Entertainment
LYV
$40.6B
| $11.9M | 0.03% |
+167,000
| New | +$11.3M |
|
505
Monolithic Power Systems
MPWR
$70.1B
| $11.9M | 0.03% |
+67,000
| New | +$10.7M |
|
|
MIK
506
DELISTED
Michaels Stores, Inc
MIK
| $11.9M | 0.03% |
+1,472,153
| New | +$12.4M |
|
|
CHMA
507
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $11.9M | 0.03% |
2,400,000
| – | – |
|
508
BP
BP
$116B
| $11.9M | 0.03% |
315,000
+50,000
| +19% | +$1.9M |
|
|
CCXI
509
DELISTED
ChemoCentryx, Inc.
CCXI
| $11.9M | 0.03% |
+300,000
| New | +$5.27M |
|
510
Novartis
NVS
$297B
| $11.8M | 0.03% |
+125,000
| New | +$11.2M |
|
511
Cadence Design Systems
CDNS
$93.6B
| $11.7M | 0.03% |
168,227
-10,900
| -6% | -$731K |
|
512
Pinnacle West Capital
PNW
$12.2B
| $11.7M | 0.03% |
129,663
-6,200
| -5% | -$559K |
|
513
NRG Energy
NRG
$28.3B
| $11.6M | 0.03% |
292,920
-658,000
| -69% | -$26M |
|
514
Invesco
IVZ
$13.1B
| $11.6M | 0.03% |
645,669
+179,400
| +38% | +$3.06M |
|
515
Vornado Realty Trust
VNO
$7.41B
| $11.6M | 0.03% |
174,221
+29,400
| +20% | +$1.9M |
|
516
Pultegroup
PHM
$24.1B
| $11.6M | 0.03% |
298,400
-8,600
| -3% | -$334K |
|
|
ADVM
517
DELISTED
Adverum Biotechnologies
ADVM
| $11.5M | 0.03% |
100,000
| – | – |
|
518
TSMC
TSM
$2.1T
| $11.3M | 0.03% |
+195,000
| New | +$10.3M |
|
519
Spyre Therapeutics
SYRE
$8.54B
| $11.2M | 0.03% |
58,744
| – | – |
|
520
Molson Coors Class B
TAP
$7.79B
| $11.2M | 0.03% |
208,136
-10,400
| -5% | -$559K |
|
521
Alaska Air
ALK
$5.29B
| $11.1M | 0.03% |
164,350
-36,800
| -18% | -$2.51M |
|
522
Arrowhead Research
ARWR
$11.9B
| $11.1M | 0.03% |
175,000
-250,000
| -59% | -$12.4M |
|
523
MarketAxess Holdings
MKTX
$5.71B
| $11.1M | 0.03% |
29,250
-1,600
| -5% | -$587K |
|
524
Syndax Pharmaceuticals
SNDX
$1.69B
| $11M | 0.03% |
1,250,000
| – | – |
|
525
Select Water Solutions
WTTR
$2.3B
| $10.9M | 0.03% |
1,175,388
-175,000
| -13% | -$1.41M |
|
Similar funds
Adage Capital Partners's Q4 2019 Portfolio in Review
As of Q4 2019, Adage Capital Partners held 801 positions worth $40.7B, down 0.01% from $40.7B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Adage Capital Partners withdrew a net $3.46B in Q4 2019, closing 90 positions and reducing 396 holdings. Its most notable exit was Celgene Corp, an estimated $1.48B position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 16% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Bristol-Myers Squibb worth $142M.
- Adage Capital Partners's largest Q4 2019 buy was Bristol-Myers Squibb: 2,207,539 shares worth $142M.
- Adage Capital Partners added most to RTX Corp in Q4 2019, an estimated $165M increase.
- Adage Capital Partners's biggest Q4 2019 reduction was Apple, cutting an estimated $136M.
- Adage Capital Partners fully exited Celgene Corp in Q4 2019, selling an estimated $1.48B.
- Adage Capital Partners's ten largest holdings make up 20% of its $40.7B portfolio in Q4 2019.
- Adage Capital Partners opened 88 new positions and closed 90 in Q4 2019.
- Adage Capital Partners's portfolio value fell 0.01% quarter-over-quarter to $40.7B.
Based on Adage Capital Partners's 13F filing for Q4 2019, filed 14 Feb 2020.